Sight drug deal ends High Court challengeBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1039 (Published 25 July 2008) Cite this as: BMJ 2008;337:a1039
- Clare Dyer, BMJ
More than 120 patients of Warwickshire Primary Care Trust with wet age related macular degeneration are to receive treatment with a new drug on the NHS pending approval by the National Institute for Health and Clinical Excellence (NICE).
The settlement, under which Novartis, the manufacturer of ranibizumab (Lucentis), has agreed to provide the drug free after 14 treatment cycles on the NHS, was brokered by High Court judge Mr Justice Forbes after three patients challenged the trust’s refusal to fund treatment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial